9 Other revenues

 

 

 

€ million

2018

2017

Revenue generated by means of profit-sharing agreements

11

16

Upfront payments, milestone payments and reimbursements

34

133

Contract manufacturing revenues

83

91

Total other revenue

128

240

 

 

 

The revenue generated through profit-sharing agreements relates mainly to revenue from the co-promotion of Dafiro®.

During 2018, UCB received milestone payments and reimbursements from different parties, mainly:

  • Sanofi for collaboration and development of innovative anti-inflammatory small molecules;
  • Otsuka for co-development of E Keppra® and Neupro® in Japan;
  • Daiichi Sankyo for Vimpat® in Japan;
  • Astellas for Cimzia® in Japan;
  • Biogen for co-development of antibody dapirolizumab pegol.

The revenue from contract manufacturing activities is mainly linked to the entering into toll manufacturing agreements after divestiture of established brands.